Anavex Life Sciences Corp. (AVXL): New Bullish Coverage

AVXL – Roth Capital initiates as a buy, $6PT. This price target represents a 107.61% upside over the stock’s previous closing price of $2.89.


Update: As of Dec. 10, 2018, this bullish analyst call has returned -27.34%.


Key Facts Surrounding This News Item


  • AVXL had a POWR Rating of D (Sell) coming into today.
  • AVXL was 12.98% above its 10-Day Moving Average coming into today.
  • AVXL was 12.81% above its 20-Day Moving Average coming into today.
  • AVXL was -0.53% below its 50-Day Moving Average coming into today.
  • AVXL was -15.60% below its 100-Day Moving Average coming into today.
  • AVXL was -29.69% below its 200-Day Moving Average coming into today.
  • AVXL had returned -10.25% year-to-date leading up to today’s news, versus a +2.22% return from the benchmark S&P 500 during the same period.

More Info About Anavex Life Sciences Corp. (AVXL)


Anavex Life Sciences Corporation is engaged in the discovery and development of drugs for the treatment of Alzheimer’s disease, central nervous system diseases, and pain and various cancers. The company was founded in 2006 and is based in New York, New York. View our full AVXL ticker page with ratings, news, and more.

AVXL at a Glance

AVXL Current POWR Rating™
Overall POWR Rating™
AVXL Current Price $2.10 2.33%
More AVXL Ratings, Data, and News

AVXL Price Reaction

The day of this event (Mar. 8, 2018)
AVXL Closing Price$3.07 6.23%
AVXL Volume648,800
92.85% from avg
Leading up to this event
AVXL 1-mo return10.73%
After this event
AVXL 1-day return3.02%
AVXL 3-day return5.09%
AVXL 5-day return5.86%

AVXL Price Chart


The Top Stocks For 2019

More Anavex Life Sciences Corp. (AVXL) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All AVXL News
Page generated in 0.8991 seconds.